Lumeda Announces Appointment of Jason Pesterfield to Board of Directors

Experienced medical industry executive to help company implement strategic plan in its next phase of clinical studies and market development Rocky Hill, Connecticut – July 20, 2021 – Lumeda Inc., a medical technology company advancing Photodynamic Therapy (PDT) as an intraoperative adjuvant treatment for patients during lung cancer surgery, today announced the appointment of Jason Pesterfield to its board of …

Lumeda Announces Closing of $4.3M Series A Financing with Clinical Studies Due to Commence in 2021

Funding to advance product design and clinical testing as the company strives to improve outcomes for lung cancer patients Rocky Hill, Connecticut – April 8, 2021 – Lumeda Inc., a medical technology company advancing Photodynamic Therapy (PDT) as an intraoperative adjuvant treatment for patients during lung cancer surgery, today announced the closing of its Series A financing. The round was …

Lumeda Announces Appointment of Alexander Zinke as Chief Executive Officer

Experienced medical industry executive to lead the company in its next phase of commercialization and growth Rocky Hill, Connecticut – October 15, 2020 – Lumeda Inc., a biophotonics systems company advancing photodynamic therapy (PDT) for treating cancer, today announced the appointment of Alexander (Sandy) Zinke as Chief Executive Officer. Mr. Zinke will also join the company board of directors.    …

LASER FOCUSED – Rocky Hill photonics team shifts entrepreneurial focus, setting sights on cancer treatment…

Over the past 13 years, two longtime friends and a small team based in Rocky Hill have broken their way into the global energy sector, developing acoustic and fiber-optic sensors and software that have enabled more efficient production in mile-deep oil and gas wells as well as improved monitoring of electric grid cables.

Now Trevor MacDougall and Paul E. Sanders — serial entrepreneurs who have founded two companies and successfully sold one to a Canadian energy firm in 2012 for a hefty but undisclosed sum — are pivoting their fiber-optic sensor technology platform to improve a lung cancer treatment called photodynamic therapy, or PDT. Their latest company, Lumeda — backed by an initial $1-million investment from Connecticut Innovations and Branfordbased Cycle Venture Partners — is hoping to get U.S. Food & Drug Administration approval within the next two years for an optical device that automates the targeting and dosage of laser light to the site of a newly removed thoracic tumor.

PDT 2020

PDT 2020 November 5, 2020 Ecole Nationale Supérieure des Industries Chimiques (ENSIC) Virtual Event The third annual PDT symposium is devoted to all aspects of clinical photodynamic therapy.  Clinical PDT will be discussed in terms of photodynamic diagnosis or therapy, instrumentation, photosensitizers, light dosimetry and monitoring, mathematical modelling, and cellular mechanisms.

Lumeda Announces Formation of its Scientific Advisory Board

Prominent medical and scientific experts to help company advance development of PDT products Rocky Hill, Connecticut – June 22, 2020 – Lumeda Inc. (“Lumeda”), a biophotonics systems company advancing photodynamic therapy (PDT) for treating cancer, today announced the formation of its Scientific Advisory Board with the appointment of a panel of medical and scientific experts who will provide critical medical, …

Lumeda Enters License Agreement with Roswell Park Comprehensive Cancer Center

Company secures exclusive rights for intraoperative photodynamic therapy in the treatment of non-small cell lung cancer Rocky Hill, Connecticut – June 25, 2020 – Lumeda Inc. (“Lumeda”), a biophotonics systems company formed to advance photodynamic therapy for treating cancer, today announced the company has entered a license agreement with Roswell Park Comprehensive Cancer Center of Buffalo, New York (“Roswell Park”).  …